6533b7d1fe1ef96bd125d501

RESEARCH PRODUCT

Patient Reported Outcome in metastatic breast cancer and platinum-resistant recurrent ovarian cancer treated with metronomic cyclophosphamide ± methotrexate: PROmetronomic - FoR.UM 19-02193

V LinzSlavomir KrajnakKatrin AlmstedtK AnicR SchwabMartina SchmidtAnne-sophie HeimesAnnette HasenburgMarco Johannes Battista

subject

Oncologymedicine.medical_specialtybusiness.industrymedicine.diseaseMetastatic breast cancerRecurrent Ovarian CancerInternal medicineMedicinePatient-reported outcomeMethotrexatebusinessMetronomic cyclophosphamidePlatinum resistantmedicine.drughttps://doi.org/10.1055/s-0041-1730186